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Inhibition of DPP4 activity in humans establishes
its in vivo role in CXCL10 post-translational
modification: prospective placebo-controlled
clinical studies
Jérémie Decalf1,2,†, Kristin V Tarbell3,†, Armanda Casrouge1,2, Jeffrey D Price3, Grace Linder3,
Estelle Mottez4, Philippe Sultanik5, Vincent Mallet5, Stanislas Pol5, Darragh Duffy1,2,4,*,‡ &
Matthew L Albert1,2,4,6,**,‡
Abstract
Biochemical experiments, animal models, and observational stud-
ies in humans all support a role of dipeptidyl peptidase 4 (DPP4) in
the N-terminal truncation of CXCL10, which results in the genera-
tion of an antagonist form of the chemokine that limits T-cell and
NK cell migration. Motivated by the ability to regulate lymphocyte
trafficking in vivo, we conducted two prospective clinical trials to
test the effects of DPP4 inhibition on CXCL10 processing in healthy
donors and in chronic hepatitis C patients, a disease in which DPP4
levels are found to be elevated. Participants were treated daily
with 100 mg sitagliptin, a clinically approved DPP4 inhibitor.
Plasma samples were analyzed using an ultrasensitive single-
molecule assay (Simoa) to distinguish the full-length CXCL101–77
from the NH2-truncated CXCL103–77, as compared to the total
CXCL10 levels. Sitagliptin treatment resulted in a significant
decrease in CXCL103–77 concentration, a reciprocal increase in
CXCL101–77, with only minimal effects on total levels of the chemo-
kine. These data provide the first direct evidence that in vivo DPP4
inhibition in humans can preserve the bioactive form of CXCL10,
offering new therapeutic opportunities for DPP4 inhibitors.
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Introduction
Chemokines play an essential role in cell migration. Regulation of
their activity is particularly important during inflammatory
responses, determining the recruitment of immune cells to lymphoid
organs or targeting them toward injured tissues (Griffith et al,
2014). Post-translational modification of chemokines has been
shown to regulate their activity; however, in vivo evidence remains
limited to observational studies and experimental mouse models
(Moelants et al, 2013). Dipeptidyl peptidase 4 (DPP4, also known as
CD26) is a serine protease capable of removing the first two amino
acids of proteins possessing a proline or alanine in the Nterminal
penultimate position (Bongers et al, 1992). In vitro studies have
shown that DPP4-mediated N-terminal truncation of the pro-
inflammatory chemokine CXCL10 leads to the generation of an
antagonist form (Proost et al, 2001; Casrouge et al, 2011). More-
over, recent in vivo work performed in mice has demonstrated that
this truncation alters lymphocyte migration and limits infiltration of
the tumor parenchyma, a phenomenon that could be reversed using
the DPP4 inhibitor sitagliptin (Barreira da Silva et al, 2015).
A challenge for studying post-translational modifications of
chemokines is the ability to specifically monitor the different protein
forms in biological material. To overcome this, we developed
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immunoassays that discriminate the full-length agonist form of
CXCL10 (referred to as CXCL101–77, or long CXCL10) from the
NH2-truncated form generated by DPP4 cleavage (referred to as
CXCL103–77, or short CXCL10) (Casrouge et al, 2012). Accordingly,
we were able to show that elevated levels of short CXCL10 were
associated with an increased DPP4 activity, both being negative
predictors for viral clearance in chronic and acute hepatitis C (HCV)
patients (Casrouge et al, 2011; Ragab et al, 2013; Riva et al, 2014).
Taking advantage of the Simoa technology (Rissin et al, 2010), we
have now developed ultrasensitive immunoassays with these anti-
bodies, making possible the quantification of functional forms of
CXCL10 in the plasma from healthy individuals.
To provide a proof of concept for DPP4 inhibition as a means to
protect full-length CXCL10, we conducted a randomized placebo-
controlled study in healthy individuals, with the primary scientific
objective being the assessment of DPP4 inhibition on immunological
parameters. A prior report on this cohort demonstrated an effective
DPP4 inhibition and an increased concentration of active glucagon-
like peptide 1, one of the key substrates implicated in insulin
resistance (Price et al, 2013). In parallel, we undertook an investiga-
tional study to explore how sitagliptin treatment affects virus-induced
CXCL10 in chronic HCV patients (cHCV), a clinical setting in which
levels of both DPP4 and CXCL103–77 have been shown to be elevated
(Ragab et al, 2013). The findings from this report establish the basis
for repositioning DPP4 inhibitors as a potential immunotherapy.
Results
To quantify CXCL10 agonist and antagonist forms in healthy indi-
viduals, we implemented our unique immunoassays on the Simoa
platform (Fig 1A). Using these assays, we determined median levels
of total CXCL10 to be 60 pg/ml in healthy individuals (Fig 1B and
C, SV and D0 time points), within the range of what has been previ-
ously reported using other techniques (Butera et al, 2005; Duffy
et al, 2014). Long CXCL10 remained undetectable in most individu-
als, whereas short CXCL10 was detected in 30 out of 36 subjects
(83%) with concentrations ranging from 2 to 75 pg/ml, suggesting
active in vivo chemokine processing in healthy individuals.
Importantly, all the plasma samples used for the analysis of CXCL10
levels were collected in tubes containing a DPP4 inhibitor to avoid
potential extracorporeal CXCL10 processing.
In order to explore the role of DPP4 in CXCL10 truncation in vivo,
we monitored the levels of short, long, and total CXCL10 in healthy
individuals receiving a 28-day course of placebo or sitagliptin
(Fig 1B and C). DPP4 inhibition in individuals receiving sitagliptin
was confirmed by monitoring plasma DPP4 activity, which was
previously published (Price et al, 2013) and showed an inhibition
ranging from 9 to 80% (Fig EV1). We observed that 3 days after the
onset of sitagliptin treatment, the concentrations of short CXCL10
dropped significantly in individuals receiving sitagliptin, but
remained stable in donors receiving the placebo. Effect size analysis
supported the strong impact of sitagliptin on short CXCL10 when
compared to pre-therapy levels (d = 0.92). As detailed in Fig EV1,
some donors showed sporadic increases in short CXCL10 during sita-
gliptin therapy, possibly reflecting a partial recovery of DPP4 activity
(Herman et al, 2005). Moreover, three of the 27 donors showed
elevated levels of short CXCL10 during sitagliptin treatment,
reflecting natural human variability in response to the treatment. Of
note, despite the presence of short CXCL10, two of these three
donors showed a strong DPP4 inhibition.
Interestingly, the inhibition of DPP4 was associated with
the preservation of long CXCL10, as indicated by an increase in
concentration compared to pre-therapy (d = 0.27), although these
data have to be interpreted cautiously due to a large number of
patients in which long CXCL10 remained undetectable. That said,
this increase was observed at week 2 of treatment, but not at day 3
post-treatment initiation, perhaps reflecting a low level of newly
secreted CXCL10 in healthy individuals. Of note, the levels of total
CXCL10 were found to be slightly decreased during sitagliptin
treatment compared to pre-therapy levels (d = 0.33), suggesting a
limited biological impact of sitagliptin on total CXCL10 levels. That
said, the strong impact of sitagliptin on short CXCL10 indicated that
we selectively altered processing, rather than the production of the
chemokine. Finally, the modulation of short and long CXCL10 was
stable during the 28-day course of sitagliptin, returning to pre-
therapy concentrations once treatment was terminated. These
data provide direct evidence that DPP4 inhibition impacts in vivo
N-terminal truncation of CXCL10.
The data obtained in healthy individuals suggest that CXCL10
processing by DPP4 is a rapid event, as it was strongly affected 72 h
after the onset of sitagliptin therapy. Therefore, we assessed how
sitagliptin might affect higher levels of CXCL10, a hallmark of
inflammatory diseases (Van Raemdonck et al, 2015). To do so, we
monitored CXCL10 forms in three cHCV patients receiving
sitagliptin treatment (Fig 1D). Of note, as detailed in the study
design section, additional patients could not be recruited for ethical
reasons. As previously described (Casrouge et al, 2011), cHCV
patients showed elevated concentrations of short, long, and total
CXCL10 compared to healthy individuals (D0 time points).
Interestingly, sitagliptin treatment led to a decrease in short CXCL10
and an increase in long CXCL10 (Fig 1D), a trend similar to what
we observed in healthy individuals. Although striking, the impact of
sitagliptin on CXCL10 forms did not influence HCV viral loads over
the period monitored (Fig EV2).
Discussion
Overall, the finding that the agonist form CXCL101–77 was unde-
tectable in the majority of healthy individuals indicates that CXCL10
and likely other chemokines are rapidly catabolized by DPP4. The
corollary to this observation is that long CXCL10 may be considered
as a marker of recently produced CXCL10. Moreover, the lower
levels of long and short forms compared to the total plasma
concentration of CXCL10 indicate that additional processing of the
protein is probably occurring in vivo. Other proteases, such as
matrix metalloproteinases (Van den Steen et al, 2003), have been
shown to target CXCL10, but their activity in vivo and the impact on
chemokine function remain unknown (see Mortier et al (2008) for
review of subject). Action of other N-terminal aminoproteases could
also explain the trimming of CXCL103–77, acting after DPP4 removes
the penultimate proline residue, as shown in in vitro biochemical
studies using CXCL11 (Proost et al, 2007).
Our findings expose a broader putative in vivo role of DPP4 in the
regulation of cell trafficking. Notably, other chemokine substrates of
EMBO Molecular Medicine Vol 8 | No 6 | 2016 ª 2016 The Authors
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DPP4 have been defined as key mediators of stem cell migration. In
mouse studies, DPP4 inhibition has been shown to improve the
engraftment of CD34+ stem cells following umbilical cord blood
transplantation, with the mechanism of action being the protection
of agonist forms of CXCL12 (Farag et al, 2013). While our study does
not directly test a role for altered post-translational modification of
CXCL12, the similar biological processes would suggest a direct
impact on CXCR4-mediated leukocyte migration.
From a therapeutic perspective, our results establish a path
toward the secondary use of DPP4 inhibitors. Indeed, our recent
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Figure 1. Sitagliptin treatment limits DPP4-mediated N-terminal truncation of CXCL10.
A CXCL10 assay characteristics. Standard curves of the short, long, and total CXCL10 Simoa assays are shown. For each curve, the limit of detection (LOD) defined as
blank+3SD is shown as horizontal lines. The LOD was 1.7 pg/ml for long and short CXCL10 assays and 0.22 pg/ml for total CXCL10. Standard curves were fitted
using the 4-parameter logistic nonlinear regression model. Samples reporting a signal below the LOD were replaced with 1 pg/ml for short and long CXCL10.
B–D Plasma from healthy individuals receiving (B) placebo (n = 9) or (C) sitagliptin (n = 27) was analyzed by Simoa. Blood samples were collected at screening visit (SV)
and day 0 (D0) before treatment; at day 3 (D3), day 14 (W2), and day 28 (W4) under treatment; and 5 weeks after treatment interruption (W9). (D) Plasma from
chronic HCV patients receiving sitagliptin (n = 3) was collected before (D0) and weekly during sitagliptin treatment (W1 & W3). Antagonist CXCL103–77 (short
CXCL10, in blue), agonist CXCL101–77 (long CXCL10, in red), and total CXCL10 (in black) levels are shown. Each dot represents a donor, and bars are at the median.
Gray areas highlight the period under placebo or sitagliptin treatment. Statistical analysis of (B) and (C) was performed using nonparametric Friedman’s test, ns:
nonsignificant, **P < 0.01, ****P < 0.001. For (C), additional size effect analysis was performed and Cohen’s d values are reported. No statistical analysis was
performed in (D) due to sample size, nd: nondetermined.
Table 1. Clinical information.
Category Treatment Number of subjects Gender (F/M) Age - median (range) HCV genotype
Healthy Placebo 9 6/3 27 (20–61) –
Healthy Sitagliptin 27 16/11 36 (19–53) –
cHCV Sitagliptin 3 2/1 41 (38–55) 4
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mouse studies have shown that preserving agonist CXCL101–77
increases lymphocyte infiltration into tumor parenchyma and results
in an enhanced tumor immunity (Barreira da Silva et al, 2015).
Thus, these drugs may offer an opportunity to increase the
lymphocyte migration in settings such as chronic infection and
cancer. As DPP4 inhibitors are a class of widely used therapeutics
for the management of type II diabetes, they are considered to be
safe and well tolerated.
In sum, our work provides the first in vivo experimental evidence
of CXCL10 processing in humans and supports the clinical testing of
sitagliptin as either an antitumor or autoimmune therapy. Further
work will be required to better understand the impact of DPP4
inhibition in vivo and to evaluate how other forms of chemokine
post-translational modifications could influence inflammatory
responses.
Materials and Methods
Study design and protocols
The cohort of healthy individuals receiving sitagliptin or placebo
(NCT00813228) has been previously described. This study was a
double-blind, randomized trial approved by the institutional review
board of NIDDK (Price et al, 2013). Participants received 100 mg of
sitagliptin (n = 27) or placebo (n = 9) once daily for 28 days, and
the blood samples were collected longitudinally. Chronic HCV
patients receiving sitagliptin (n = 3) were recruited as part of the
INSERM-sponsored C10-54 trial (NCT01567540). The three patients
were chronically infected with HCV genotype 4 and were receiving
pegylated-interferon alpha + ribavirin therapy when they enrolled
in the study. These patients were considered difficult to treat, as
they had previously failed to achieve early virological response
(EVR) as defined by a two-log reduction in virus at 12 weeks
post-treatment. Sitagliptin treatment (100 mg daily) was given for
3 weeks and the blood samples were collected longitudinally. Of
note, the C10-54 trial was terminated prematurely due to the
approval of sofosbuvir in France for HCV genotype 4-infected
patients. The ethical implications that arose from the availability of
this novel highly efficacious antiviral therapy prevented the
continued recruitment of additional cHCV patients in our
experimental clinical study. The respective studies were approved
by the institutional review boards of the NIH and INSERM. All
participants gave written informed consent prior to inclusion in the
study, conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report. Clinical characteristics are summarized in Table 1.
Plasma was collected in BD P700 tubes, containing ethylenediamine
tetraacetic acid (EDTA) and a DPP4 inhibitor to prevent
extracorporeal cleavage of CXCL10. Plasma collected in sodium
heparin tubes was used for monitoring DPP4 activity. Samples were
stored at 80°C until analysis.
CXCL10 quantification
Plasma concentration of total (R&D clone 33036), long (CXCL101–77),
and short (CXCL103–77) CXCL10 was measured using Simoa
technology (Quanterix). Simoa assays were carried out as
previously described (Meissner et al, 2015), and additional
optimization was conducted for this study; standard curves are
presented in Fig 1A.
Statistical analysis
Differences in CXCL10 forms in healthy donors receiving either
sitagliptin or placebo were assessed by nonparametric Friedman’s
test. No statistical analysis was performed on HCV patients due to
the available sample size (n = 3). For healthy donors receiving sita-
gliptin, size effect analysis using Cohen’s d was performed to assess
the biological significance of modified CXCL10 levels. Three groups
of samples were compared; the values were obtained pre-therapy
(SV, D0), during therapy (D3, W2, and W4), and post-therapy (W9).
Cohen’s d estimates the biological significance of statistically signifi-
cant differences to be small (d  0.2), medium (d  0.5), or large
(d  1).
Expanded View for this article is available online.
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The paper explained
Problem
The N-terminal truncation of CXCL10 by DPP4 results in the genera-
tion of an antagonist form of the chemokine that limits T-cell and NK
cell migration toward infectious or tumor sites. In this work, we stud-
ied whether DPP4 inhibition in vivo by sitagliptin could limit the
generation of the antagonist form of CXCL10 in humans, which could
have the potential to boost T-cell and NK cell migration in certain
pathological contexts.
Results
Participants were treated daily with 100 mg sitagliptin, and plasma
samples were analyzed using an ultrasensitive single-molecule assay
(Simoa) to distinguish levels of the agonist (CXCL101–77), antagonist
(CXCL103–77), and total CXCL10 forms. Sitagliptin treatment resulted in
a significant decrease in antagonist CXCL10 concentration and a
reciprocal increase in the agonist form CXCL101–77 compared to
placebo controls.
Impact
Our data provide the first in vivo evidence that DPP4 inhibition in
humans can preserve the bioactive form of CXCL10. This offers new
therapeutic opportunities for DPP4 inhibitors, which could be relevant
for the development of novel cancer immunotherapies aiming at
restoring immune cell migration.
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